These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10765465)

  • 21. Progress in QSAR toxicity screening of pharmaceutical impurities and other FDA regulated products.
    Kruhlak NL; Contrera JF; Benz RD; Matthews EJ
    Adv Drug Deliv Rev; 2007 Jan; 59(1):43-55. PubMed ID: 17229485
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Zero risk and zero benefit: some thoughts on the control of genotoxic impurities.
    Grosso J
    Curr Opin Drug Discov Devel; 2009 Nov; 12(6):730-1. PubMed ID: 19894186
    [No Abstract]   [Full Text] [Related]  

  • 24. Identification, control strategies, and analytical approaches for the determination of potential genotoxic impurities in pharmaceuticals: a comprehensive review.
    Reddy AV; Jaafar J; Umar K; Majid ZA; Aris AB; Talib J; Madhavi G
    J Sep Sci; 2015 Mar; 38(5):764-79. PubMed ID: 25556762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acceptance criteria for levels of hydrazine in substances for pharmaceutical use and analytical methods for its determination.
    Kean T; Miller JH; Skellern GG; Snodin D
    Pharmeur Sci Notes; 2006 Dec; 2006(2):23-33. PubMed ID: 17691211
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmaceutical impurities and degradation products: uses and applications of NMR techniques.
    Maggio RM; Calvo NL; Vignaduzzo SE; Kaufman TS
    J Pharm Biomed Anal; 2014 Dec; 101():102-22. PubMed ID: 24853620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anticipated revisions to the current good manufacturing practice regulations.
    Mitchell CM
    Bull Parenter Drug Assoc; 1974; 28(3):146-51. PubMed ID: 4845938
    [No Abstract]   [Full Text] [Related]  

  • 28. Assuring quality of drugs by monitoring impurities.
    Ahuja SS
    Adv Drug Deliv Rev; 2007 Jan; 59(1):3-11. PubMed ID: 17218038
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A perspective on testing of existing pharmaceutical excipients for genotoxic impurities.
    Brusick DJ
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):200-4. PubMed ID: 19607870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals.
    Elder DP; Snodin D; Teasdale A
    J Pharm Biomed Anal; 2010 Apr; 51(5):1015-23. PubMed ID: 20031361
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Extractable Elements from Elastomers.
    Paskiet D; Kraft C; Tullo E; Hunter J; Zurbriggen D
    PDA J Pharm Sci Technol; 2019; 73(1):83-91. PubMed ID: 30030347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Certification of suitability of monographs of the European pharmacopoeia].
    Artiges A
    Ann Pharm Fr; 2002 Sep; 60(5):333-40. PubMed ID: 12378143
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: An Updated Literature Review.
    Jenke D
    PDA J Pharm Sci Technol; 2020; 74(3):324-347. PubMed ID: 31843988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substandard medicines in resource-poor settings: a problem that can no longer be ignored.
    Caudron JM; Ford N; Henkens M; Macé C; Kiddle-Monroe R; Pinel J
    Trop Med Int Health; 2008 Aug; 13(8):1062-72. PubMed ID: 18631318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmaceutical impurities: analytical, toxicological and regulatory perspectives.
    Basak AK; Raw AS; Yu LX
    Adv Drug Deliv Rev; 2007 Jan; 59(1):1-2. PubMed ID: 17196297
    [No Abstract]   [Full Text] [Related]  

  • 36. Relationship between HPLC precision and number of significant figures when reporting impurities and when setting specifications.
    Agut C; Segalini A; Bauer M; Boccardi G
    J Pharm Biomed Anal; 2006 May; 41(2):442-8. PubMed ID: 16472956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Panel discussion: international drug regulations and their practical application. I. Swedish experience of drug regulations and their applications.
    Liljestrand A
    Bull Parenter Drug Assoc; 1974; 28(4):153-60. PubMed ID: 4853527
    [No Abstract]   [Full Text] [Related]  

  • 38. Identification and characterization of degradation products of dicloxacillin in bulk drug and pharmaceutical dosage forms.
    Raj TJ; Bharati CH; Rao KR; Rao PS; Narayan GK; Parikh K
    J Pharm Biomed Anal; 2007 Mar; 43(4):1470-5. PubMed ID: 17125952
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Demonstration of robust host cell protein clearance in biopharmaceutical downstream processes.
    Shukla AA; Jiang C; Ma J; Rubacha M; Flansburg L; Lee SS
    Biotechnol Prog; 2008; 24(3):615-22. PubMed ID: 18410156
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemical and analytical characterization of related organic impurities in drugs.
    Görög S
    Anal Bioanal Chem; 2003 Nov; 377(5):852-62. PubMed ID: 12937879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.